Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
Central venous catheters (CVCs) are used in patient care for such purposes as the
administration of medication, fluids, blood products and for functions such as hemodialysis
and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening
bloodstream infections (BSI).
BSIs are caused by organisms from the skin's surface tracking down the catheter's outer
surface. The organisms grow on the catheter surface (catheter colonization) which is followed
by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as
high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up
to 70,000 patients in the US die each year from catheter-related BSI.
MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site,
may prevent organisms on the skin from migrating down the catheter and entering the
bloodstream and therefore decrease the incidence of catheter-related BSI in patients with
CVCs.